Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 studyResearch in context

Background: Primary immune thrombocytopenia (ITP) is an autoimmune disease, and rituximab (RTX) induces long-term effect as second-line treatments. Zuberitamab is an innovative anti-CD20 monoclonal antibody, which was first developed in China and launched in diffuse large B lymphoma. This study aime...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet regional health. Western Pacific 2024-06, Vol.47, p.101096
Main Authors: Min Xu, Jinhui Shu, Shenxian Qian, Jingming Guo, Yuping Gong, Ruibin Huang, Shuye Wang, Zeping Zhou, Guolin Yuan, Meijuan Huang, Li-E Lin, Shifeng Lou, Yanping Song, Qingchi Liu, Hu Zhou, Heng Mei, Yu Hu
Format: Article
Language:English
Subjects:
Immune thrombocytopenia
Rituximab
Safety and efficacy
Zuberitamab
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Primary immune thrombocytopenia (ITP) is an autoimmune disease, and rituximab (RTX) induces long-term effect as second-line treatments. Zuberitamab is an innovative anti-CD20 monoclonal antibody, which was first developed in China and launched in diffuse large B lymphoma. This study aimed to investigate the safety, efficacy, and anticipated therapeutic dose of zuberitamab in Chinese ITP patients. Methods: This randomised, double-blind, placebo-controlled, phase 2 study was conducted at 26 hospitals in China. Eligible patients were aged 18–70 years, had primary immune thrombocytopenia for more than 6 months, and did not respond or relapsed after previous treatment and had a pre-treatment platelet count of
ISSN:2666-6065